Brookline, MA, January 11, 2016 —

Transplant Genomics Inc. (TGI) is a molecular diagnostics company committed to improving kidney transplant outcomes through tests that support physician decisions on personalized immunosuppression. The company’s TruGraf^™ blood test relies on analysis of gene expression profiles to detect molecular signatures indicative of acute rejection, differentiating this clinical phenotype from nonimmune causes of dysfunction in kidney transplant recipients. As part of its TruGraf blood test commercialization program, TGI today announced key additions to its scientific advisory board (SAB).

TGI’s founding SAB included the following members:

Chief Scientific Advisor Dan Salomon, MD, The Scripps Research Institute
Chief Clinical Advisor Michael Abecassis, MD, MBA, Northwestern University Feinberg School of Medicine
SAB Chairman Roy First, MD, Chief Medical Officer, TGI

The founding SAB is now joined by four well-known and respected members of the transplant community whose insights and advisory input will complement and further inform TGI’s scientific direction and clinical objectives.

Bruce McManus, MD: Dr. McManus is Professor, Department of Pathology and Laboratory Medicine, University of British Columbia. He serves as the CEO for the Centre of Excellence for Prevention of Organ Failure (PROOF Centre), as Co-Director of the Institute for Heart + Lung Health and as Immediate-Past Director, UBC James Hogg Research Centre/Centre for Heart Lung Innovation. Dr. McManus’ interests focus on mechanisms, consequences, detection and prevention of injury and aberrant repair involved in inflammatory diseases of the heart and blood vessels. His work on multi-omic biomarker signature development occurs in a cross-disciplinary setting where answers are critically enabled by computational sciences. Dr. McManus has co-authored approximately 380 peer-reviewed publications and more than 50 chapters. He has edited four books. He is co-holder of numerous patents.
Goran Klintmalm, MD: Dr. Klintmalm is Chairman and Chief, Simmons Transplant Institute, Baylor University Medical Center, and Director, Dallas Liver Transplant Program. Dr. Klintmalm performed the first liver transplant in Texas at Baylor University Medical Center nearly 30 years ago. He has developed one of the largest and most reputable transplant programs in the world. He is the author or co-author of more than 600 publications in transplantation. Dr. Klintmalm is the co-editor of the principal textbook in liver transplantation and has published four other textbooks and written 33 textbook chapters, 309 articles in peer-reviewed journals and 73 articles in non-peer-reviewed journals.
Parmjeet Randhawa, MD: Dr. Randhawa is a Professor of Pathology and a member of the Division of Transplant Pathology at the University of Pittsburgh Medical Center. He has special expertise in the evaluation of kidney transplant biopsies that is reflected in 28 book chapters and 14 reviews. He is also an internationally known transplant pathologist who contributed to the development of The Banff Schema for Renal Allograft Pathology. His work has helped better define the significance of several pathologic lesions in the transplanted kidney. His research on the epidemiology, molecular biology, immunology and pharmacology of polyomavirus BK and clinical aspects of transplantation pathology is reported in the form of more than 200 publications in highly regarded journals. He has served as a member of the education committee, abstract reviewer, session chair and faculty presenter at several major conferences in transplantation. He is on the Editorial Board of The American Journal of Kidney Diseases, has served as a member of several NIH study sections, and is a recipient of The American Society of Transplantation Established Investigator Award.
Bruce Kaplan, MD: Dr. Kaplan is the Kathy and Harry Lentsch Professor of Medicine and Professor of Surgery and Pharmacology, Medical Director of the Abdominal Transplant Program and Section Chief of Nephrology at the University of Arizona College of Medicine. His research interests include kidney transplantation and kidney pharmacology, and he is internationally recognized in immunosuppressive pharmacology and outcomes in patients. Dr. Kaplan has published more than 220 peer-reviewed papers (with some of the most cited in the field) and 30 book chapters and is the author of a new book on immunopharmacology.

“We are thrilled to have attracted to our SAB such prominent physicians and scientists who share our interest in transforming transplant patient management,” said Stan Rose, PhD, President & CEO of Transplant Genomics. “This distinguished group will work closely with our management team to identify opportunities in transplant diagnostics and immunosuppressive patient management, prioritize our product development portfolio and provide strategic advice on addressing the future needs of the transplant community.”

About Transplant Genomics Inc.

Transplant Genomics Inc. (TGI) is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. Working with the transplant community, TGI is commercializing a suite of tests enabling diagnosis and prediction of transplant recipient immune status. Test results derived from gene expression profiles will support clinicians with information to optimize immunosuppressive therapy, enhance patient care and improve transplant outcomes. Test services are offered through TGI’s CLIA lab in Pleasanton, CA. www.transplantgenomics.com

MEDIA CONTACT:
Darren Lee
dlee@transplantgenomics.com